GB202315863D0 - Formulations - Google Patents
FormulationsInfo
- Publication number
- GB202315863D0 GB202315863D0 GBGB2315863.7A GB202315863A GB202315863D0 GB 202315863 D0 GB202315863 D0 GB 202315863D0 GB 202315863 A GB202315863 A GB 202315863A GB 202315863 D0 GB202315863 D0 GB 202315863D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2315863.7A GB202315863D0 (en) | 2023-10-17 | 2023-10-17 | Formulations |
| PCT/EP2024/077436 WO2025068591A1 (en) | 2023-09-28 | 2024-09-30 | Intranasal formulations for treating obstructive sleep apnea |
| TW113137345A TW202529757A (en) | 2023-09-28 | 2024-09-30 | Intranasal formulations for treating obstructive sleep apnea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2315863.7A GB202315863D0 (en) | 2023-10-17 | 2023-10-17 | Formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202315863D0 true GB202315863D0 (en) | 2023-11-29 |
Family
ID=88863810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2315863.7A Ceased GB202315863D0 (en) | 2023-09-28 | 2023-10-17 | Formulations |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202315863D0 (en) |
-
2023
- 2023-10-17 GB GBGB2315863.7A patent/GB202315863D0/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202117828D0 (en) | New formulations | |
| IL290356A (en) | Larazotide formulations | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| IL284691A (en) | Formulations | |
| GB202204171D0 (en) | Novel formulations | |
| IL319149A (en) | Upadacitinib formulation | |
| GB202018889D0 (en) | Formulations | |
| GB202009684D0 (en) | Formulations | |
| GB202009685D0 (en) | Formulations | |
| IL321617A (en) | Bezuclastinib formulations | |
| GB202315863D0 (en) | Formulations | |
| GB202307059D0 (en) | Formulations | |
| GB202216961D0 (en) | 5-meo-mt formulations | |
| GB202115127D0 (en) | Formulations | |
| GB202115121D0 (en) | Formulations | |
| GB202103762D0 (en) | Formulations | |
| GB202103780D0 (en) | Formulations | |
| GB202103785D0 (en) | Formulations | |
| GB202018250D0 (en) | Formulations | |
| GB202018251D0 (en) | Formulations | |
| GB202108259D0 (en) | Novel formulations | |
| GB202004814D0 (en) | Novel formulations | |
| GB202004811D0 (en) | Novel Formulations | |
| GB202417829D0 (en) | Formulations | |
| IL323027A (en) | Formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |